NIKA PHARMACEUTICALS, INC

Nika Pharmaceuticals shows no cyber incidents or material red-flag 8-K filings in our 90-day monitoring window, which represents a baseline of operational stability. However, absence of recent events does not establish absence of risk—the full $49 Report pulls a 12-month event history, financing and dilution trajectory, and AI-powered risk signals across governance, cash runway, and shareholder structure. The complete analysis adds quantified dilution risk scores, contextual 8-K review, and forward indicators that our real-time feed alone cannot capture. The full $49 Report adds comprehensive risk scoring and 12-month historical context to round out your due diligence.